FDA Guide Cuts Animal Testing for New Drugs
Published Date: 3/19/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers use new, smarter testing methods that can reduce animal testing and better predict human safety. This affects drug developers who want to submit safer, more reliable data for approval. Comments are open until May 18, 2026, so get involved early to shape the final rules and possibly save time and money in drug development.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Encourages Use of NAMs in Submissions
If you develop drugs, FDA published a draft guidance that gives a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The guidance covers using nonclinical NAM data to support regulatory submissions (for example, investigational new drug applications and biologics license applications), encourages early engagement with drug review divisions, and is open for comment through May 18, 2026.
NAMs Apply to OTC Topical Monograph Orders
If you make nonprescription topical (OTC) drugs, the draft guidance says NAMs can be used to support nonclinical data for OTC monograph orders issued under section 505G of the FD&C Act. FDA issued this draft guidance in part to satisfy the requirement under section 505G(r)(2)(B), and it is open for comment through May 18, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in